New York, Feb 25, 2026, 12:40 EST — Regular session
- Eli Lilly shares slipped, following a choppy two-day stretch for stocks tied to obesity drugs.
- Traders are starting to question whether the GLP-1 narrative has shifted—pricing now matters as much as supply.
- On deck: new product launches, incoming trial results, and regulatory calls still to come.
Eli Lilly and Company stock slipped 0.8% to $1,033.36 as of 12:40 p.m. EST, after moving in a range from $1,030.56 to $1,053.63 earlier. Shares have been tossed around this week, caught up in a flurry of sector news on obesity drugs.
Lilly’s valuation hinges on the outlook for its surging diabetes and weight-loss portfolio. If the market narrative tilts from a scramble for supply to a price war, those expectations can get knocked back fast.
Investors are still working out just how long this surge in demand for GLP-1 drugs—medicines that imitate a gut hormone to suppress appetite and bring down blood sugar—might last. The major issue now isn’t so much demand, but who’s footing the bill, and how much they’re willing to pay.
Lilly on Monday announced it received U.S. FDA clearance for a four-dose KwikPen version of its weight-loss drug Zepbound, letting users get a month’s supply from just one device. The company put the starting price at $299 per month for out-of-pocket buyers at the 2.5 mg level, with all six dose strengths set to roll out.
On that same day, Novo Nordisk released late-stage trial results for its next-gen obesity drug, CagriSema. The data showed CagriSema trailing Lilly’s Zepbound in a direct comparison, which triggered sharp moves in both stocks. “This is a worst-case scenario,” Markus Manns of Union Investment told Reuters, highlighting Novo’s uphill battle to close the distance. Reuters
Tuesday’s attention landed squarely on pricing moves. Novo Nordisk announced a 50% cut to the U.S. list price of Wegovy and a 35% trim for Ozempic, bringing both down to $675 a month starting Jan. 1, 2027. The company pitched the change as a benefit for patients whose out-of-pocket payments follow the list price. Bernstein’s Courtney Breen, though, called the step “not a silver bullet”—and stressed, this doesn’t kick off any sort of price war. Reuters
The push and pull between improved devices and clinical wins, and the squeeze from pricing, has Lilly acting less like a safe pharma name lately and more like a headline-driven play. Some traders pointed to today’s drop and questioned if this is just investors locking in gains after the stock’s rally, or something deeper—a sign that GLP-1 pricing assumptions could be in for a broader rethink.
Risks cut both ways here. Should list-price reductions cascade into steeper rebates and heavier discounting, Lilly’s margins might shrink—even if sales volumes keep rising. That could force investors to rethink their earnings models.
Another wrinkle: new trial data could upend the narrative, while regulators might shift their stance—either clamping down or easing up—on cheaper compounded alternatives that have stepped in during branded shortages.
Regulation looms as the next key driver for the sector. Lilly is eyeing an April verdict from U.S. regulators on its competing weight-loss pill—a moment that could shift the contest from injectables to oral treatments, and turn up the heat on pricing throughout the category.
